Team siliconindia

• Supraflex Cruz shows lower failure rates in high-risk patients
• TUXEDO-2 trial proves it matches top US stent Xience
• Indian medical innovation praised for technical excellence

An Indian-made heart stent, Supraflex Cruz, has earned major global recognition after demonstrating a lower failure rate in high-risk patients compared to the US-made stent Xience. The findings were presented at a global cardiology conference this week.

The results come from the TUXEDO-2 trial, conducted in India under the leadership of Dr Upendra Kaul, Chairman and Dean of Delhi’s Batra Hospital, along with Co-Chairman Dr Sripal Bangalore and Project Director Dr Priyadarshini Arambam. The trial rigorously compared Supraflex Cruz with the international market leader Xience and confirmed that the Indian stent is non-inferior.

Data from the trial revealed that Supraflex Cruz had significantly lower Target Lesion Failures (TLF), which include serious outcomes like cardiac death, heart attacks, and the need for repeat procedures. The Indian stent also showed a numerically lower rate of heart attacks over one year.

Dr Kaul highlighted that the trial results are a testament to the technical excellence of Indian medical device manufacturing. The stent is produced by a company in Surat and represents a significant step forward for homegrown healthcare innovations.

Also Read: Philips and Nicolab Join Forces to Strengthen AI-Driven Stroke Care in India

The global cardiology community praised the achievement, noting that Indian medical devices are now gaining recognition for quality, reliability, and innovation. Experts believe this success will boost confidence in Indian-made medical technologies worldwide.

Supraflex Cruz’s performance in the trial strengthens India’s position in advanced cardiovascular interventions and demonstrates that locally developed devices can compete with the best international alternatives.